comparemela.com

Latest Breaking News On - முடிவு பரிசோதனை - Page 1 : comparemela.com

Decision Diagnostics Saga Continues As Investors Bring Suit - Corporate/Commercial Law

To print this article, all you need is to be registered or login on Mondaq.com. In December, the SEC filed a  complaint against Decision Diagnostics and its CEO, Keith Berman, for falsely claiming the company had developed a finger prick blood test that could instantaneously detect COVID-19.  As stated in its complaint, the SEC temporarily suspended trading of Decision Diagnostics securities on April 23, 2020. Now, investors have brought suit as well.  Three institutional investors  claim the company – which was already in financial distress as a result of  alleged misappropriations by Berman – falsely disclosed it was developing an at-home COVID-19 test nearing

Decision Diagnostics Saga Continues as Investors Bring Suit | Proskauer - Corporate Defense and Disputes

Decision Diagnostics Saga Continues as Investors Bring Suit | Proskauer - Corporate Defense and Disputes
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.

DECN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – DECN

Home / Top News / DECN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – DECN DECN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – DECN NEW YORK, March 14, 2021 (GLOBE NEWSWIRE) WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Decision Diagnostics Corp. (OTC: DECN) between March 3, 2020 and December 17, 2020, inclusive (the “Class Period”), of the important March 16, 2021 lead plaintiff deadline. SO WHAT: If you purchased Decision Diagnostics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.